Chariot Biosciences
Chariot Biosciences develops next-generation cell and gene therapies for chronic diseases, focusing on innovative, long-lasting solutions that minimize the need for frequent injections. The company's proprietary platform is based on engineered symbiotic microbes designed to provide sustained delivery of therapeutic proteins and peptides after a single injection. Chariot targets chronic conditions such as Gaucher disease, diabetes, and cancer, aiming to improve patient adherence, reduce logistical challenges, and replace standard frequent biologic dosing.
Industries
N/A
Chariot Biosciences
Products
A technology platform based on engineered symbiotic microbes designed to provide sustained production and delivery of therapeutic proteins or peptides for chronic disease management.
A technology platform based on engineered symbiotic microbes designed to provide sustained production and delivery of therapeutic proteins or peptides for chronic disease management.
Expertise Areas
- Chronic disease therapeutics
- Synthetic biology
- Implantable cell therapies
- Enzyme replacement therapy
Key Technologies
- Synthetic biology platforms
- Engineered symbiotic microbes
- Implantable cell therapy systems
- Therapeutic gene engineering
Key People
Co-founder, CEO
Co-founder
Executive Director
Interim CFO
Co-founder, CEO
Co-founder
Executive Director
Interim CFO
News & Updates
Patents pending for the engineered microbes, the therapeutic gene constructs, the delivery platform, and their medical applications.
Patents pending for the engineered microbes, the therapeutic gene constructs, the delivery platform, and their medical applications.